Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Queensland Health
Harvard Business School
US Department of Justice
QuintilesIMS
Argus Health
Colorcon
Boehringer Ingelheim
AstraZeneca
Cerilliant

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,119,859

« Back to Dashboard

Which drugs does patent 9,119,859 protect, and when does it expire?

Patent 9,119,859 protects XTORO and is included in one NDA.

This patent has twenty patent family members in fourteen countries.
Summary for Patent: 9,119,859
Title:Methods for treating otic infections
Abstract: The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.
Inventor(s): Stroman; David W. (Irving, TX), Chowhan; Masood A. (Arlington, TX), Appell; Kenneth C. (Burleson, TX)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:13/967,897
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,119,859

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF ACUTE OTITIS EXTERNA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,119,859

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,536,167 Methods for treating ophthalmic, otic, or nasal infections ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,119,859

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I460181 ➤ Sign Up
Taiwan 201102395 ➤ Sign Up
Russian Federation 2570731 ➤ Sign Up
Russian Federation 2012103458 ➤ Sign Up
Mexico 2012000136 ➤ Sign Up
South Korea 101541823 ➤ Sign Up
South Korea 20120114211 ➤ Sign Up
Japan 2015134827 ➤ Sign Up
Japan 5784012 ➤ Sign Up
Japan 2012532115 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
UBS
McKesson
Boehringer Ingelheim
Julphar
QuintilesIMS
Medtronic
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot